X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Through the acquisition, Jazz Pharmaceuticals will have access to Redx Pharma KRAS (Kirsten rat sarcoma virus) inhibitor program for all clinical development, regulatory, manufacturing, and commercialization activities.
Lead Product(s): Undisclosed
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Jazz Pharmaceuticals
Deal Size: $880.0 million Upfront Cash: $10.0 million
Deal Type: Acquisition February 07, 2024
Details:
Under the termination, Jounce Therapeutics will not merge with Redx. The business combination was supposed to aim the development of RXC007, a next-generation selective ROCK2 inhibitor, which is currently being assessed in a Phase 2a study in idiopathic pulmonary fibrosis.
Lead Product(s): RXC007
Therapeutic Area: Oncology Product Name: RXC007
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Jounce Therapeutics
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Termination April 03, 2023
Details:
Through the business combination, the combined group's priority will be the development of RXC007, a next-generation selective ROCK2 inhibitor, which is currently being assessed in a Phase 2a study in idiopathic pulmonary fibrosis (IPF).
Lead Product(s): RXC007
Therapeutic Area: Oncology Product Name: RXC007
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Jounce Therapeutics
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Merger February 23, 2023
Details:
RXC007 is an oral, selective Rho Associated Coiled-Coil Containing Protein Kinase 2 (ROCK2) inhibitor which is currently being assessed in a Phase 2a study in idiopathic pulmonary fibrosis (IPF).
Lead Product(s): RXC007
Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: RXC007
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 09, 2023
Details:
A second arm of the trial, evaluating RXC004 in combination with the anti-PD-1 antibody nivolumab in patients with MSS mCRC, is expected to commence in the first half of 2022 once a recommended dose has been established in the ongoing Phase 1 dose escalation combination trial.
Lead Product(s): RXC004,Denosumab
Therapeutic Area: Oncology Product Name: RXC004
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 15, 2021
Details:
Under the terms of the collaboration agreement, Redx will be responsible for research and preclinical development activities up to Investigational New Drug (IND) submission.
Lead Product(s): Undisclosed
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: DiscoveryProduct Type: Small molecule
Partner/Sponsor/Collaborator: Jazz Pharmaceuticals
Deal Size: $420.0 million Upfront Cash: $10.0 million
Deal Type: Collaboration September 09, 2020
Details:
Under the terms of the exclusive global agreement, AstraZeneca will take RXC006 forward into clinical development, targeting fibrotic diseases including idiopathic pulmonary fibrosis (IPF).
Lead Product(s): RXC006
Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: RXC006
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: AstraZeneca
Deal Size: $377.0 million Upfront Cash: Undisclosed
Deal Type: Licensing Agreement August 04, 2020
Details:
Recruitment to Redx's phase 1/2a clinical trial of RXC004, an oral porcupine inhibitor, has been halted in line with the policy of the five recruiting hospital centres in the UK.
Lead Product(s): RXC004
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 23, 2020
Details:
Preclinical data with compounds from Redx’s ROCK2 programme have demonstrated robust anti-fibrotic effects in a range of industry-standard in vivo models.
Lead Product(s): RXC007
Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Undisclosed
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 09, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
